Literature DB >> 21909658

Intravitreal injection of bevacizumab combined with macular grid laser photocoagulation for macular edema in branch retinal vein occlusion.

Atsushi Hayashi1, Tatsuya Yunoki, Akio Miyakoshi, Keiichi Mitarai, Takahiro Fujino, Shuichiro Yanagisawa.   

Abstract

PURPOSE: To evaluate the effects of combined therapy of intravitreal injections of bevacizumab (IVB) and additional macular grid laser photocoagulation for recurrent macular edema in branch retinal vein occlusion (BRVO).
METHODS: This was a retrospective interventional case series in which 44 eyes of 44 patients with macular edema due to BRVO were studied. The mean follow-up term was 77.2 ± 12.4 weeks. All patients underwent IVB as a primary therapy. After two to three IVB, 19 of the 44 eyes (43.2%) underwent laser photocoagulation in the macular edema area to prevent the recurrence of the edema. In the other 25 eyes (56.8%), macular edema was successfully treated with IVB only. Visual acuity and central macular thickness (CMT) were examined during the follow-up.
RESULTS: The mean visual acuity and the mean CMT in both groups improved significantly after the IVB. Following macular grid laser photocoagulation for recurrent macular edema, the mean visual acuity was maintained for 24 weeks, however, the mean CMT increased significantly after 12 weeks.
CONCLUSIONS: Additional grid laser photocoagulation for recurrent macular edema in BRVO after IVB maintained mean visual acuity with limited effects on the further recurrence of macular edema.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21909658     DOI: 10.1007/s10384-011-0087-2

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  19 in total

Review 1.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Authors:  Napoleone Ferrara; Kenneth J Hillan; Hans-Peter Gerber; William Novotny
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.

Authors:  Mineo Kondo; Nagako Kondo; Yasuki Ito; Shu Kachi; Masato Kikuchi; Tetsuhiro R Yasuma; Ichiro Ota; Miyake Kensaku; Hiroko Terasaki
Journal:  Retina       Date:  2009-10       Impact factor: 4.256

3.  Macular edema in branch retinal vein occlusion: prognosis and management.

Authors:  F A Gutman
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1977 May-Jun

4.  Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.

Authors:  Hidetaka Noma; Hideharu Funatsu; Makiko Yamasaki; Hidetoshi Tsukamoto; Tatsuya Mimura; Takashi Sone; Koji Jian; Ikuo Sakamoto; Kensuke Nakano; Hidetoshi Yamashita; Atsushi Minamoto; Hiromu K Mishima
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

5.  The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology.

Authors:  E Stefánsson
Journal:  Acta Ophthalmol Scand       Date:  2001-10

6.  Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion.

Authors:  A Arnarsson; E Stefánsson
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-03       Impact factor: 4.799

7.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup
Journal:  Ophthalmology       Date:  2010-04-24       Impact factor: 12.079

8.  Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.

Authors:  Vincenzo Russo; Antonio Barone; Emanuele Conte; Francesco Prascina; Andrea Stella; Nicola Delle Noci
Journal:  Retina       Date:  2009-04       Impact factor: 4.256

9.  Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.

Authors:  Thomas Ach; Alexandra E Hoeh; Karen B Schaal; Alexander F Scheuerle; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-09       Impact factor: 3.117

10.  Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.

Authors:  Taichiro Miyake; Osamu Sawada; Masashi Kakinoki; Tomoko Sawada; Hajime Kawamura; Kazumasa Ogasawara; Masahito Ohji
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-29       Impact factor: 4.799

View more
  8 in total

1.  Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.

Authors:  Francesco Pichi; Ahmed Mohammed Elbarky; Tarek Roshdy Elhamaky
Journal:  Int Ophthalmol       Date:  2017-12-22       Impact factor: 2.031

2.  Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment.

Authors:  Yasuhiro Iesato; Akira Imai; Takao Hirano; Yuichi Toriyama; Toshinori Murata
Journal:  Jpn J Ophthalmol       Date:  2016-01-22       Impact factor: 2.447

3.  Branch retinal vein occlusion-associated subretinal hemorrhage.

Authors:  Yuki Muraoka; Akitaka Tsujikawa; Tomoaki Murakami; Ken Ogino; Kazuaki Miyamoto; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2013-03-19       Impact factor: 2.447

4.  Intravitreal bevacizumab alone or combined with macular laser photocoagulation for recurrent or persistent macular edema secondary to branch retinal vein occlusion.

Authors:  Takafumi Hirashima; Tomoyuki Chihara; Toshitaka Bun; Takao Utsumi; Miou Hirose; Hideyasu Oh
Journal:  J Ophthalmol       Date:  2014-07-07       Impact factor: 1.909

Review 5.  A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion.

Authors:  Juan Lyn Ang; Sarah Ah-Moye; Leah N Kim; Vuong Nguyen; Adrian Hunt; Daniel Barthelmes; Mark C Gillies; Hemal Mehta
Journal:  Eye (Lond)       Date:  2020-04-20       Impact factor: 3.775

6.  The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients.

Authors:  Toshinori Murata; Mineo Kondo; Makoto Inoue; Shintaro Nakao; Rie Osaka; Chieko Shiragami; Kenji Sogawa; Akikazu Mochizuki; Rumiko Shiraga; Yohei Ohashi; Takeumi Kaneko; Chikatapu Chandrasekhar; Akitaka Tsujikawa; Motohiro Kamei
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

7.  Comparison of the efficiency of anti-VEGF drugs intravitreal injections treatment with or without retinal laser photocoagulation for macular edema secondary to retinal vein occlusion: A systematic review and meta-analysis.

Authors:  Weijie Zou; Yuanyuan Du; Xiaoyan Ji; Ji Zhang; Hongping Ding; Jingqiao Chen; Tao Wang; Fangfang Ji; Jiang Huang
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

8.  Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion.

Authors:  Jia-Kang Wang; Pei-Yuan Su; Yung-Ray Hsu; Yun-Ju Chen; Fang-Ting Chen; Ying-Yu Tseng
Journal:  J Ophthalmol       Date:  2016-04-12       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.